Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas E Witzig

Showing results (271-280 of 387) with videos related to

Pageof 39
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemiaIrene M Ghobrial, Morie Gertz, Betsy Laplant, et al.
Blood|April 30, 2015
The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphomaThomas E Witzig, Craig Reeder, Jing Jing Han, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 7, 2019
Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With ImmunochemotherapyYucai Wang, Umar Farooq, Brian K Link, et al.
Blood Advances|December 24, 2025
Comprehensive Analysis of Subtype-Specific Outcomes and Management in Castleman Disease: A 20-Year Cohort StudyYoshito Nishimura, Thomas M Habermann, Morie A Gertz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2006
Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disordersAnne J Novak, Deanna M Grote, Steven C Ziesmer, et al.
Haematologica|November 25, 2017
Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppressionSean I Tracy, Thomas M Habermann, Andrew L Feldman, et al.
European Journal of Haematology|February 8, 2014
Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplantRahma Warsame, Soo Mee Bang, Shaji K Kumar, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 24, 2026
No association of prior administration of selected vaccines with lymphoma prognosisGeorge A Cholack, Verena Hinder, Raphael Mwangi, et al.
Leukemia & Lymphoma|April 25, 2019
Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practicePaul J Hampel, Wei Ding, Timothy G Call, et al.
Leukemia & Lymphoma|October 15, 2020
Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemiaMadugodaralalage D S K Gunaratne, Alexander J Sahakian, Jithma P Abeykoon, et al.
Pageof 39

Showing results (271-280 of 387) with videos related to

Sort By:
Pageof 39
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemiaIrene M Ghobrial, Morie Gertz, Betsy Laplant, et al.
Blood|April 30, 2015
The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphomaThomas E Witzig, Craig Reeder, Jing Jing Han, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 7, 2019
Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With ImmunochemotherapyYucai Wang, Umar Farooq, Brian K Link, et al.
Blood Advances|December 24, 2025
Comprehensive Analysis of Subtype-Specific Outcomes and Management in Castleman Disease: A 20-Year Cohort StudyYoshito Nishimura, Thomas M Habermann, Morie A Gertz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2006
Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disordersAnne J Novak, Deanna M Grote, Steven C Ziesmer, et al.
Haematologica|November 25, 2017
Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppressionSean I Tracy, Thomas M Habermann, Andrew L Feldman, et al.
European Journal of Haematology|February 8, 2014
Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplantRahma Warsame, Soo Mee Bang, Shaji K Kumar, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 24, 2026
No association of prior administration of selected vaccines with lymphoma prognosisGeorge A Cholack, Verena Hinder, Raphael Mwangi, et al.
Leukemia & Lymphoma|April 25, 2019
Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practicePaul J Hampel, Wei Ding, Timothy G Call, et al.
Leukemia & Lymphoma|October 15, 2020
Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemiaMadugodaralalage D S K Gunaratne, Alexander J Sahakian, Jithma P Abeykoon, et al.
Pageof 39